NAT-POMALIDOMIDE CAPSULE

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

POMALIDOMIDE

Доступно од:

NATCO PHARMA (CANADA) INC

АТЦ код:

L04AX06

INN (Међународно име):

POMALIDOMIDE

Дозирање:

3MG

Фармацеутски облик:

CAPSULE

Састав:

POMALIDOMIDE 3MG

Пут администрације:

ORAL

Јединице у пакету:

15G/50G

Тип рецептора:

Prescription

Резиме производа:

Active ingredient group (AIG) number: 0155290003; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2023-02-22

Карактеристике производа

_NAT-POMALIDOMIDE Product Monograph _
_ _
_ _
_Page 1 of 61_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NAT-POMALIDOMIDE
Pomalidomide Capsules
1 mg, 2 mg, 3 mg and 4 mg
Antineoplastic Agent
Immunomodulatory Agent
ATC Code: L04AX06
Natco Pharma (Canada) Inc.
Date of Initial Approval:
2000 Argentia Road, Plaza 1, Suite 200
October 08, 2020
Mississauga, Ontario
L5N 1P7
Date of Revision:
September 16, 2022
Submission Control No: 263035
_NAT-POMALIDOMIDE Product Monograph _
_ _
_ _
_Page 2 of 61_
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 6
4.3 Administration
........................................................................